ArticleDrugs - real world outcomes2026
Patient‑Reported Satisfaction in Relapsing-Remitting Multiple Sclerosis: Advantages of At‑Home Self‑Administered Subcutaneous Ofatumumab Versus Other High‑Efficacy Therapies.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis is an immune-mediated disorder characterized by demyelination and neurodegeneration. Disease-modifying therapies are available with a range of mechanisms of action, efficacies, safety profiles, places and routes of administration, and degrees of patient autonomy; however, comprehensive evaluations of satisfaction with high-efficacy therapies in patients with multiple sclerosis are lacking.
objectiveWe aimed to evaluate satisfaction of patients treated with high-efficacy therapies for relapsing-remitting multiple sclerosis and identify factors influencing preferences and acceptance, focusing on the perceived impact of administration routes on quality of life, daily activities, and treatment burden.
methodsWe conducted a cross-sectional survey of 208 adults diagnosed with relapsing-remitting multiple sclerosis who were receiving high-efficacy therapies for at least 6 months between February and April 2025 at Italian MS centers. Data were collected using a structured questionnaire designed for this study. Domains included: (I) Temporal and Organizational Burden of Therapy, (II) Perceived Impact of Therapy, (III) Therapy Administration Experience, and (IV) Decision-Making Involvement Experience.
resultsA non-parametric analysis revealed that more favorable scores on the domains of (I) Temporal and Organizational Burden of Therapy, (II) Perceived Impact of Therapy, and (III) Therapy Administration Experience were associated with treatment with subcutaneous ofatumumab (n = 90), compared to the other high-efficacy therapies such as natalizumab (n = 55), ocrelizumab (n = 59), and alemtuzumab (n = 4) [all n = 118, p < 0.001]. Fewer than one in four patients recalled being offered the possibility of self-administering high-efficacy therapies at home.
conclusionsSubcutaneous ofatumumab treatment, a therapy self-administered at home, was associated with more favorable experiences compared to other high-efficacy therapies, highlighting the importance of shared decision making and organizational and logistical factors when selecting therapies for multiple sclerosis.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.